HB 2145 Washington House · 2025-2026 Regular Session

Protecting patient access to discounted medications and health care services through Washington's health care safety net by preventing manufacturer limitations on the 340B drug pricing program.

HB 2145 prohibits drug manufacturers from restricting how 340B-covered safety net providers (like community health centers, HIV clinics, and tribal health centers) access discounted medications. It specifically bans manufacturers from denying or limiting delivery of 340B drugs to these providers or their contracted pharmacies, and prevents them from requiring data sharing as a condition for drug access. The law allows covered entities to sue violators for up to $5,000 per day per violation and requires penalties for noncompliance. This directly protects low-income patients who rely on affordable medications through Washington's safety net providers.

Issues: ✓ Healthcare

Bill status in committee 1 of 4 stages cleared

Introduction

Dec 2025

Committee Review

Floor Vote

Governor

Introduced Dec 15, 2025 Last action Feb 9, 2026

Maddy AI version diff · 2 comparisons

What changed between versions

Bill → Substitute Bill · 5 edits

MODERATE

The bill was renumbered from H-2460.2 to H-3141.1 and transferred to the Health Care & Wellness committee. The text was updated to replace specific terms like '340B drug pricing program' with the shorter '340B program' and changed 'distributor' to 'third party' in several sections. Most significantly, the bill now requires covered entities and manufacturers to submit detailed annual reports to the Department of Health regarding drug costs, savings usage, and patient demographics, a requirement that was absent in the original version.

Scope change

The bill's scope regarding reporting requirements was expanded to include mandatory annual data submissions from both covered entities and manufacturers to the state Department of Health.

TECHNICAL

The bill number changed from H-2460.2 to H-3141.1, and the sponsor list was updated to reflect committee referral.

DEFINITION

The term '340B drug pricing program' was shortened to '340B program' throughout the text for consistency.

The definition of prohibited actors in Sections 3 and 4 was changed from 'distributor' to 'third party acting on behalf of a manufacturer'.

REQUIREMENT

New reporting requirements were added, mandating that covered entities and manufacturers submit detailed annual data to the Department of Health regarding drug costs, savings usage, and patient demographics.

ENFORCEMENT

A new penalty of $1,000 per day was established for covered entities or manufacturers that fail to submit the required reports on time.

Floor votes

How they voted

No floor votes recorded yet.

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Feb 9, 2026

Committee

Referred to Rules 2 Review.

lower

Feb 9, 2026

Lower · Passed

Minority; without recommendation.

lower

Feb 9, 2026

Lower · Passed

Minority; do not pass.

lower

Feb 9, 2026

Lower · Passed

Executive action taken in the House Committee on Appropriations at 10:30 AM.

lower

Feb 6, 2026

Lower · Passed

Public hearing in the House Committee on Appropriations at 10:30 AM.

lower

Jan 28, 2026

Committee

Referred to Appropriations.

lower

Jan 23, 2026

Lower · Passed

Minority; without recommendation.

lower

Jan 23, 2026

Lower · Passed

Minority; do not pass.

lower

Jan 23, 2026

Lower · Passed

Executive action taken in the House Committee on Health Care & Wellness at 8:00 AM.

lower

Jan 20, 2026

Lower · Passed

Public hearing in the House Committee on Health Care & Wellness at 1:30 PM.

lower

1 primary · 40 co-sponsors